Adverse cutaneous reactions to antituberculosis drugs.
Holdiness
M R
MR
D000152:Acne Vulgaris / Q000139:chemically induced; D000328:Adult; D000583:Amikacin / Q000009:adverse effects; D000995:Antitubercular Agents / Q000009:adverse effects*; D004342:Drug Hypersensitivity / Q000209:etiology; D004977:Ethambutol / Q000009:adverse effects; D005000:Ethionamide / Q000009:adverse effects; D005260:Female; D006801:Humans; D007538:Isoniazid / Q000009:adverse effects; D008297:Male; D008875:Middle Aged; D010383:Pellagra / Q000139:chemically induced; D010859:Pigmentation Disorders / Q000139:chemically induced; D011515:Prothionamide / Q000009:adverse effects; D011718:Pyrazinamide / Q000009:adverse effects; D012293:Rifampin / Q000009:adverse effects; D012871:Skin Diseases / Q000139:chemically induced*; D013307:Streptomycin / Q000009:adverse effects; D013828:Thioacetazone / Q000009:adverse effects
D000995:Antitubercular Agents; D011718:Pyrazinamide; D011515:Prothionamide; D000583:Amikacin; D004977:Ethambutol; D013828:Thioacetazone; D005000:Ethionamide; D007538:Isoniazid; D012293:Rifampin; D013307:Streptomycin